ASCO肺癌热点演示文稿.pptVIP

L Zhang, et al ASCO 2011. # 7511 L Zhang, et al ASCO 2011. # 7511 ITT population Gefitinib (n=148) Placebo (n=148) p HR (95% CI) PFS Median (month) 4.8 2.6 0.0001 0.42 (0.32, 0.54) 6-month ( %) 47.3 15.0 12-month ( %) 33.2 2.9 No. events, n (%) 124 (83.8) 144 (97.3) OS Median (month) 18.7 16.9 0.2109 0.83 (0.61, 1.12) 6-month ( %) 82.2 84.9 12-month ( %) 68.8 66.0 No. events, n (%) 79(53.4) 93(62.5) ORR(%) 23.6 0.7 0.0001 57.0 (7.53, 431) DCR(%) 71.6 50.7 0.0001 2.66 (1.61, 4.40) L Zhang, et al ASCO 2011. # 7511 Gefitinib Placebo HR (95% CI) EGFR mut+ n 15 15 0.17 (0.07, 0.42) Median PFS